New findings on cancer

The invention is based on strengthening the body's immune system by creating a new type of immune cell - in combination with taking some oral drugs to stimulate their hyperinfection to directly destroy the cancer cell.

Know more about metastasis

When a cancer begins to spread throughout the body - the scientific term is called metastasis - it is always the moment of the deadliest transformation of cancer (UT). If there is no metastasis, UT can be generally interpreted as not dangerous. Indeed, less than 10% of deaths from pre-cancerous tumors, and more than 90% of deaths are due to metastasis to vital organs of the body such as the liver, lungs, bones and brain.

Dr. Patricia S. Steeg
(Photo: cancer.gov)

Although chemotherapy and other therapeutic techniques are more likely to last longer than the lives of people with metastatic UT disease, yet there are no drugs that have a special treatment to stop this process. . That's because metastasis is still something mysterious to scientists.

Dr. Patricia S. Steeg, Head of the Women's Cancer Department at the Molecular Medicine Laboratory at the National Cancer Institute (NCI), said that for the first time in years, she was more optimistic than ever. Out: ' Therapy is revealing positive results, we will soon apply them to clinical trials . In general, we are much more excited and excited than we did 5-10 years ago . '

Complexity of metastasis has led many studies to fall into dead end. Metastatic research is both costly and time-consuming, requiring extensive research on animals to monitor the movement of UT cells. Dr Danny Welch, professor of pathology at the University of Alabama at Birmingham, said that most scientists also avoid this complex area: ' There are less than 100 professionals worldwide today. research to better understand the extent of metastatic activity '.

In many mouse experiments, researchers modified DMS genes (inhibiting metastatic defects) and found that cancer cells spread to other places but did not exist in places they came. In epidemiological studies, some of the genes identified above help scientists predict the metastasis of UT and the viability of patients. Laboratories are now beginning to test the factors that can activate the DMS gene or renovate it.

Other researchers aim to try to stop the development of micro metastatic blood cells (microscopic metastases) in the process of angiogenesis. One of the first things that a metastatic micro cell has to do to multiply is to collect new blood vessels, according to Dr. Lynn M. Matrisian. Vascular inhibitors are not very successful when used alone, but they seem to help prolong the lives of some patients when combined with chemotherapy , according to Dr. Lee M. Ellis, Professor. UT Surgery and Biology at UT MD Anderson Center.

Understanding these advances helps us to know exactly what metastasis is - as well as many other processes (inside metastasis) - rather than just knowing a simple mechanism, and helping us to differentiate the difference. special in each type of UT. According to the researchers, the new findings indicate that each type of metastasis should be handled separately and thoroughly and not generic. Dr. Patricia S. Steeg said: 'They have in common, on the cellular level, but the new finding shows the opposite, each type of metastasis is completely different, so we need to develop. treatment for specific regions.

We used to think of just one metastatic treatment. But now, pharmaceutical companies need to realize that they must look directly at the secondary factors of UT disease. Every new progress and discovery can save many patients, but that is only part of human knowledge of UT disease. Every time new tumors form metastases to other organs, researchers must re-examine their underlying knowledge and search for potential culprits, thus seeing through the roots of metastasis. .

Creating lymphocytes is capable of destroying cancer

In the tireless struggle of scientists to prevent UT disease, one of the most serious fatal diseases of humanity, Gustave Rossy Academy recently in Ville Juif - French Republic, a central The medical center that specializes in the treatment of UT diseases has published an invention that brings new hope in treating this disease. The discovery is based on the body's immune system (HMD) enhancement by creating a new type of MD cell - the new name is called chlosphide (lymphocyte) in combination with the use of some oral drugs to stimulate Prefer their superficial effects to directly destroy cancer cells.

Sysème immunitaire (Sysème immunitaire) is the body's defense system against the penetration of diseases including some types of lymphatic cells (TB) circulating in the blood vessels with the function of detection, finding, kill germs, viruses, pathogens, including UT cells invading the body. If the HMD is impaired, it will prevent the body from succumbing to other pathogens attacking, causing death of the patient.

For UT disease even in cases where the body is not damaged by HMD, malignant cells still appear very ' crafty ' that can deceive the task of detection and mistakenly think of the Benign cells are not only undetectable but also prevent it from destroying them, since the body cannot resist the disease.

With that ' paradoxical ' remedy, French scientists at Gustave Rossy Academy have focused on research, conducting a hybrid method (hybride) to create a new phosphorus, named afterphosphorus lkdc ( lkdc is the acronym for lymphocyte killer directly cancer, which is responsible for detecting and destroying UT cells directly. In order to quickly increase the number of these new lulphide lkdc needs the support of two drugs: Gilvec and Intélkin II (Interleukine II). Two experiments on mice were conducted. In the first experiment, in two groups of mice treated with melanoma (melanoma), one group received 30,000 TB of lkdc / 1 in the tumor, the second group received 30,000 old lymphocytes of HMD.

After 20 days in the first group of rats over a dozen, the tumors had disappeared. In the second group, UT is still developing, many children have died. In the second experiment, the researchers did not inject TB lkdc on tumors of two groups of mice that had metastatic on the lung but for the first group to take the drugs Gilvec and Inteclin II to allow the body to rapidly produce cells. lkdc. After 15 days, in the first group metastasis disappeared while in the metastatic control group spread to both lungs. Electron microscopy showed the presence in the lungs of the first group of mice a lot of TB lkdc.

Since then, there has been evidence of a significant increase in cancer killers, a powerful weapon of HMD by the combination of Gilvec and Intel's II.

A clinical trial will now be conducted on the human body: One side of the female patients with ovarian cancer with conventional chemotherapy, on one side in patients with malignant tumors in the stomach and intestine with the brand name Gilvec and Intélinkin II. Let's wait for the experimental results to be made with great hope to be announced soon.

Luong Vinh Khang - Le Dao